ORPHAN Cures Act

1. 01

   How would excluding orphan drugs from Medicare price negotiation affect costs for elderly patients with rare diseases compared to other Medicare beneficiaries?

2. 02

   What evidence exists that delaying price negotiation on orphan drugs encourages pharmaceutical investment in treatments for rare conditions?

3. 03

   Which pharmaceutical companies would benefit most from this exemption, and how might it change their pricing strategies for rare disease treatments?

Cosponsor writes these to seed civic discussion — they aren't user posts. Sign in to reply.